Theratechnologies Inc T.TH

$3.50

[SPCEO1]

The price of THTX is stuck at $3.50 and has been for several weeks now. This lack of movement, despite news of insider buying and the appointment of Dr. Rothenberg as well as interst in TH's SORT1+ platform and a huge bull run in the market is not a normal situation and one wonders what forces are at work that is leading to the stock flatlining at this level. 

I don't have any great explanations, unfortunately.

Could there be both a buyer and a seller of some size who both think $3.50 is the price they want to transact at and their respective algos are just working with each other over a number of weeks. Could Cantor be acquiring a position for later disposition at a profit when they put out a report complimentary of TH in preparation for the ATM offering?

Of course, we cannot really know what is going on, but it sure is odd.

[jfm1330]

The volume is very low. It is wait and see on both sides. We all wait for the same thing: oncology results.

[Wino115]

Let's see if PL can break the stalemate with a few smiles and tidbits at the CS conference. He needs to find an adjective that is better than all the previous ones he's used to describe the SORT1+ Platform .... we've heard "exquisite data", "new treatment paradigm", "superlative data".   I would vote for "nothing differnent from pre-clinical

[qwerty22]

"Following in the footsteps of Trop 2 (Trodelvy,  +$300 est. 2021 sales) and Nectin 4 (Padcev, +$300 est 2021 sales) THTX are openning up a third major new target for cancer treatment with their Sort 1 technology. Proof of  efficacy data supports further investment in this first in class drug platform"

[Wino115]

oooh, even better!  Excellent idea.  Perhaps apply for that open IR job.  They should put the thought of those 2 drugs in investors minds and mention Sortilin is a major target and overexpresses the worse off the cancer stage. 

[SPCEO1]

I suppose those that want to be pre-postioned prior to the oncology results are already mostly there with a few late traders still likely to come in, especially if Paul gives some indications about the exact timing of when those results might become available next week at CS First Boston. Given what we do know, taking the short side of this news event would seem to be quite brave. I am not sure

[SABBOBCAT]

Isnt Cantor the one doing the ATM? If so they are likely research restricted on it and wont publish anything until it is complete. 

[SPCEO1]

They are the broker behind th ATM but I am not certain about the rules on when they can and cannot publish. 

[Wino115]

I recall looking that up and it did appear that as long as they were on the hook for the sell through, they were restricted. I didn't run it by any old compliance friends but that's what I found on some website describing how an ATM works.

[Wino115]

I do recall retiredIRA mentioning we were approaching tax selling time for harvesting some of those loses folks may still have. THat's likely some of it and it's exacerbated by the ridiculously low volume. Plenty of people seem interested to pick up shares at these levels though, so that's a good sign.  Even if all we get is the dosage, which we know is at least 1.5x plus the

[PWIB123]

It's hard not to be cynical when the stock literally pauses at $3.50 over-and-over again.  

[SPCEO1]

THTX has closed trading at exactly $3.50 in eight of the last eighteen trading sessions. It has closed at $3.49 in a further three and between $3.51 and $3.53 in another five. That is weird. But if, after all this time, THTX was not weird, we would be kind of shocked, right?

[muslix1]

It looks like a company that is going to be bought or a company that is going to issue financing... my call..

[CreatingApe]

Could it have to do with the ATM financing?? Please God no.. not yet.....

[Dcutter101]

Shares O/S are not increasing, has to be  institutional buying with a fill at $3.50

[SPCEO1]

Shares outstanding will only increase when the company updates its quarterly financials. I don't think we can expect to hear about ATM sales until the company announces it.

[CreatingApe]

Ughh that makes me nervous. I really hope Dcutter is right

[PWIB123]

That would suggest that institutional buying is propping the stock up, and if they weren't there, we would be seeing additional share price loss.  I've been debating selling and harvesting tax losses and then buying back in after 30 days.  It sounds like the odds are lower that we'll get news that would meaningfully move the stock forward by year-end.  Maybe now is the

[scarlet1967]

Why would they start printing shares at "ridiculously low share price". I certainly hope the board members have the courage to wait this time round before pulling the trigger. The oncology results at this stage with or without efficacy are statically not enough to based their decision on although good results are encouraging going into phase1b basket trial. The trial still ongoing so no

[Wino115]

We know at the quarterly they had at least one at the 420 level, where they mentioned the SAE2 neutropenia (non febrile) and that they continued dosing one other at that level at least.  I think the protocol would have been to figure out the issues with that one patient but to have 3 at that level of 420. Then if nothing comes up, wasn't there one more level to try and then that woudl be

[scarlet1967]

I remember that slide, as per the information there they will dose one patient at the time until DLT then they will use a dosage just below and move on with groups of three. They did confirm during last CC they are doing one patient at the time still and no DLT thusfar but they are close to MTD which is confusing as they still are dosing one patient at the time I guess what I am trying to say is

[jfm1330]

Marsolais said that what they see in the phase Ia is in line with what they saw in the preclinical experiments and in preclinical they achieved three times the MTD of docetaxel alone. One thing we don't know about this patient with neutropenia at 420 mg/m2 is if he has a cancer overexpressing sortilin or not. I still think that toxicity will happen at lower doses on patients with a cancer not

[qwerty22]

It's reasonable to say that if the drug is going to work then it's probably going to work at 2-3x docetaxel levels. If it can't perform at those levels then too much of the raisin d'tre of this drug is broken. So it's reasonable to say they have the dose range to explore efficacy. All they need to do is give us some efficacy. That's all !!! The first sniff of efficacy

[realitycheck4u]

This post has been removed in accordance with Community Policy

[retiredRIA]

Tax loss harvesting makes sense.....just hope PL doesn't come out with an announcement that penalizes you for your patience!  If I had losses I might do the same thing!

[SPCEO1]

That has to be considered a possibility. Obviously, that would not be a good sign for cancer if true. Leah's leaving might be understandable if that is what is going on. Last I heard, however, is they had no intention of using it now and I hope that proves true. Given the superlatives used to describe the cancer recently, it would be surprising if they were using the ATM prior to the release